Clinical Efficacy of Hepatic Artery Chemoembolization Combined with Lenvatinib in the Treatment of Locally Advanced Hepatocelluar Carcinoma
Objective To observe the clinical efficacy and adverse drug reaction of transcatheter arterial chemoembolization(TACE)combined with ranvartinib mesylate targeted therapy in patients with locally advanced hepatocelluar carcinoma(HCC).Methods From January 2021 to October 2022,seventy-eight patients with locally advanced HCC diagnosed in the Oncology Department of the First Affiliated Hospital of Henan University were selected.They were randomly divided into a treatment group and a control group,with 39 patients in each group.The control group patients were only treated with TACE,while the treatment group patients were treated with lenvatinib mesylate capsules combined with TACE.Objective response rate(ORR),disease control rate(DCR),median overall survival(OS),median progression-free survival(PFS)and the influence on the expression levels of serum des-gamm-carboxy prothrombin(DCP),Golgi apparatus protein 73(GP73)and alpha fetoprotein(AFP)were observed.Results The ORR and DCR of patients in the treatment group(56.41％and 74.36％)were higher than those(33.33％and 46.15％)in the control group(P＜0.05).The expression levels of serum DCP,GP73 and AFP in the treatment group were lower than those in the control group(P＜0.05).The incidence of hypertension,fatigue,joint myalgia and proteinuria in the treatment group was higher than that in the control group(P＜0.05).The median PFS and median OS in the treatment group were 11.6 and 18.5 months,respectively,which were longer than those in the control group at 7.2 and 13.8 months(P＜0.05).Conclusion TACE combined with lenvatinib mesylate capsules has reliable clinical efficacy in locally advanced HCC patients who cannot be surgically removed,prolongs patient survival time,tolerates controllable adverse reactions,and reduces serum DCP,GP73 and AFP expression levels,providing a new choice for clinical treatment.
万方数据
维普
